HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Council Focused On Japanese Regs For Quasi-Drugs, Anti-Aging Included

This article was originally published in The Rose Sheet

Executive Summary

Japan's Ministry of Health, Labor and Welfare vows to keep up discussions with stakeholders - including U.S. industry - on "ways to increase the transparency and efficiency" of its approval process for quasi-drugs, which include anti-aging products

You may also be interested in...



Policy Panel: Council Execs Highlight Regulatory Priorities At Home & Abroad

The Personal Care Products Council welcomes FDA's reenergized science focus by expanding its Cosmetic Ingredient Review program, with plans to review almost 50 percent more substances this year than last

Policy Panel: Council Execs Highlight Regulatory Priorities At Home & Abroad

The Personal Care Products Council welcomes FDA's reenergized science focus by expanding its Cosmetic Ingredient Review program, with plans to review almost 50 percent more substances this year than last

ICCR Addresses Cosmetic Labeling, Nanotechnology At First Meeting

The International Cooperation on Cosmetics Regulation invites the cosmetics industry to generate and submit data showing that U.S. consumers understand the meaning of "trivial names" on product labeling

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016288

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel